At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 23 enrolled
Drug / intervention
Belumosudil Tablet +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 3-way, Crossover, Randomized, Open-label Study in Healthy Subjects Comparing the Bioavailability of Belumosudil (KD025) Tablets in Fed and Fasted States and Relative Bioavailability of Tablets and Capsules in the Fed State
In Brief
A Phase 1 clinical trial evaluating Belumosudil Tablet and Belumosudil Capsule for Bioavailability. Completed, enrolled 23 participants across 1 site.
Detailed Summary
Phase 1 bioavailability study to evaluate the pharmacokinetics (PK) and tolerability/safety of the belumosudil tablet formulation in the fasted and fed states and compared to the belumosudil capsule formulation in the fed state.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBioavailability
CountriesUnited Kingdom
CollaboratorsQuotient Clinical
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedSep 2015
Primary CompletionOct 2015
TodayJul 2026
First PostedSep 23, 2015
Enrollment StartSep 1, 2015
Primary CompletionOct 12, 2015
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 10.8 years ago
Interventions
Belumosudil Tabletdrug
Belumosudil Capsuledrug